Press Detail

/
PRESS RELEASE

Biotest AG opens three further plasmapheresis centers in Hungary and the USA

- Inauguration opening of new collection center in Budapest marks doubling of capacities in Hungary

- Two new centers already opened in USA in 2013, with two additional centers to follow in Florida

Dreieich, October 11, 2013 - Today, Biotest is celebrating the opening of its second plasmapheresis center in Budapest. The center, one of the most modern of its type in Europe, is located in the newly-built Corvin shopping center situated in the city's heart, providing space for up to 35 donor beds across an area of around 800 m². The company is thereby boosting its plasma sourcing capacities and continuing to grow as part of its successful expansion activities.

The first plasmapheresis center in Budapest was opened in 2009 by Plazmaszolgálat Kft., the subsidiary of Plasma Service Europe GmbH that was newly founded at that time and is in turn wholly-owned by Biotest AG. 'The success of the first center confirmed our expectations entirely. Based on the experience and knowledge we gained there, we are very pleased to open a further collection center in the metropolis of Budapest. With our Hungarian subsidiary celebrating its 25^th anniversary today, Hungary is an optimal location offering good infrastructure and an excellent educational level, especially in the medical area,' as Prof. Gregor Schulz, CEO of Biotest AG underscored. The plasma collected there undergoes further processing exclusively at Biotest. With this capacity expansion, the company is able to serve the Hungarian market exclusively with products extracted from Hungarian plasma.

Biotest is also charting continuous growth in the USA. Twelve plasmapheresis centers were in operation there at the end of 2012, of which eleven stations are already operational seven days a week. The company has continued to expand its plasma collection activities in the USA during the course of 2013 to date and has already opened two new centers in Florida, one in Orlando and the other in Melbourne. Moreover, a new center in Royal Palm Beach, Florida, will be followed by a further center in the course of the next nine months. With these additions, Biotest will soon be operating 16 plasmapheresis centers in the USA. Prof. Schulz explains the strategic reasons for the expansion as follows: 'With the expansion of our own plasma collection capacities we are responding to continued high demand for the resultant end-products. With a high degree of our own supply sourcing, we are protecting ourselves against price and supply fluctuations on the global market, guaranteeing sufficient supplies of high-quality plasma at all times.' Regularly conducted audits at all centers ensure that the high statutory and internal quality standards are fully met at all times, also during this growth phase.

Human blood plasma is the basic material to produce plasma protein preparations that are used to treat various diseases of the immune system and the hematopoietic (blood-forming) system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups.

Disclaimer

This document contains forward-looking statements about macroeconomic trends as well as about the business position, results of operations, financial position and net assets of Biotest AG and of its subsidiaries. These statements are based on the company's current plans, estimates, forecasts and expectations, and to this extent are subject to risks and uncertainty factors that could mean that actual trends diverges from expected trends. These forward-looking statements are valid only at the time when this document is published. Biotest does not intend to update the forward-looking statements, and enters into no such related obligation.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic medicines. With a value chain that spans preclinical and clinical development through to global marketing, Biotest specializes predominantly on the clinical immunology, hematology as well as intensive and emergency medicine application areas. In its plasma protein portfolio Biotest develops and markets immunoglobulins, clotting factors and albumins which are produced on the basis of human blood plasma, and which are utilized in diseases of the immune system or of the hematopoietic (blood-building) systems. Biotest also develops monoclonal antibodies, including for the rheumatoid arthritis and hematologic cancer indications. Biotest employs more than 1,700 staff worldwide. The preference shares of Biotest AG are listed in Deutsche Börse's SDAX equity index.

Biotest AG, Landsteinerstrasse 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit, Telephone: +49 (0) 6103 801-4406,
E-mail: investor_relations@biotest.de
Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard
Regulated Unofficial Market (OTC): Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart